New drug combo aims to wipe out lingering cancer cells in aggressive lymphoma
NCT ID NCT07257055
Summary
This study is testing if adding a drug called glofitamab after standard initial treatment can better control a fast-growing type of blood cancer called mantle cell lymphoma (MCL). It is for adults newly diagnosed with a high-risk form of MCL who have not yet started treatment. The main goal is to see if this approach can eliminate any remaining traces of cancer cells in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.